BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival
Discover the revival of the biotech sector, with IPOs resurging and promising weight loss drug potential, despite facing ...
This IPO Biotech Stock Could Be the Next Eli Lilly
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
Hosted on MSN6d
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rises On Upsized IPO
BioAge Labs stock rose Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.
The Business Journals6d
BioAge seeks nearly $200 million in initial public offering
Kristen Fortney, cofounder and CEO of BioAge Labs. From the San Francisco Business Times. BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs ...
More Companies Explore Going Public as the IPO Market Shows Signs of Thawing
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...
Investing6d
Bioage Labs Inc (BIOA)
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...
RTW Biotech notes BioAge Labs' USD198 million initial public offering
(Alliance News) - RTW Biotech Opportunities Ltd on Friday noted that portfolio firm BioAge Labs Inc has completed a USD198 million initial public offering.
Reuters6d
Weight-loss drug developer BioAge raises $198 mln in U.S. IPO
Sept 25 (Reuters) - BioAge Labs has raised $198 million after pricing its upsized U.S. initial public offering at the midpoint of the targeted range at $18 per share, the weight-loss drug ...